KR102569226B1 - 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 - Google Patents

운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 Download PDF

Info

Publication number
KR102569226B1
KR102569226B1 KR1020177012838A KR20177012838A KR102569226B1 KR 102569226 B1 KR102569226 B1 KR 102569226B1 KR 1020177012838 A KR1020177012838 A KR 1020177012838A KR 20177012838 A KR20177012838 A KR 20177012838A KR 102569226 B1 KR102569226 B1 KR 102569226B1
Authority
KR
South Korea
Prior art keywords
atoms
group
formula
alkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177012838A
Other languages
English (en)
Korean (ko)
Other versions
KR20170082532A (ko
Inventor
헨리 조셉 브레슬린
오렌 길라드
Original Assignee
아트린 파마슈티컬스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아트린 파마슈티컬스 엘엘씨 filed Critical 아트린 파마슈티컬스 엘엘씨
Publication of KR20170082532A publication Critical patent/KR20170082532A/ko
Application granted granted Critical
Publication of KR102569226B1 publication Critical patent/KR102569226B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
KR1020177012838A 2014-10-13 2015-10-13 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 Active KR102569226B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462063176P 2014-10-13 2014-10-13
US62/063,176 2014-10-13
US201562104274P 2015-01-16 2015-01-16
US62/104,274 2015-01-16
PCT/US2015/055317 WO2016061097A1 (en) 2014-10-13 2015-10-13 Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20170082532A KR20170082532A (ko) 2017-07-14
KR102569226B1 true KR102569226B1 (ko) 2023-08-22

Family

ID=55654998

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177012838A Active KR102569226B1 (ko) 2014-10-13 2015-10-13 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제

Country Status (12)

Country Link
US (3) US9663535B2 (cg-RX-API-DMAC10.html)
EP (1) EP3207031B1 (cg-RX-API-DMAC10.html)
JP (1) JP6678679B2 (cg-RX-API-DMAC10.html)
KR (1) KR102569226B1 (cg-RX-API-DMAC10.html)
CN (1) CN107108527B (cg-RX-API-DMAC10.html)
AU (1) AU2015333738B2 (cg-RX-API-DMAC10.html)
BR (1) BR112017007708B8 (cg-RX-API-DMAC10.html)
CA (1) CA2963973C (cg-RX-API-DMAC10.html)
ES (1) ES2879441T3 (cg-RX-API-DMAC10.html)
IL (1) IL251595B (cg-RX-API-DMAC10.html)
MX (1) MX389198B (cg-RX-API-DMAC10.html)
WO (1) WO2016061097A1 (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica
WO2017180723A1 (en) * 2016-04-12 2017-10-19 Atrin Pharmaceuticals LLC Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use
WO2018218197A2 (en) 2017-05-26 2018-11-29 Board Of Regents, The University Of Texas System Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase
HRP20240368T1 (hr) 2017-07-13 2024-08-30 Board Of Regents, The University Of Texas System Heterociklički inhibitori atr kinaze
JP7290627B2 (ja) 2017-08-17 2023-06-13 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
US11267809B2 (en) 2017-09-14 2022-03-08 The Board Of Trustees Of The Leland Stanford Junior University BAF complex modulating compounds and methods of using the same
JP7341156B2 (ja) 2018-03-16 2023-09-08 ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム Ａｔｒキナーゼの複素環式阻害剤
CN110357905B (zh) * 2018-03-26 2021-10-01 武汉誉祥医药科技有限公司 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途
WO2020014524A1 (en) 2018-07-12 2020-01-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for reversing hiv latency using baf complex modulating compounds
CN110950890B (zh) * 2018-09-27 2022-07-01 北京赛林泰医药技术有限公司 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂
KR20210097124A (ko) 2018-10-30 2021-08-06 리페어 세라퓨틱스 인크. 화합물, 약제 조성물, 및 화합물 제조 방법 및 atr 키나제 억제제로서의 이것들의 사용 방법
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
WO2023201320A1 (en) 2022-04-14 2023-10-19 Atrin Pharmaceuticals LLC Atr inhibitors
KR20250023494A (ko) 2022-06-15 2025-02-18 아스트라제네카 아베 암 치료를 위한 병용 요법
WO2025181153A1 (en) 2024-03-01 2025-09-04 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with pi3k alpha inhibitors
WO2025229051A1 (en) 2024-05-03 2025-11-06 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with antiandrogen agent
WO2025233224A1 (en) 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy
WO2026064575A1 (en) 2024-09-19 2026-03-26 Aprea Therapeutics, Inc. Methods for treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071837A1 (en) 2008-12-19 2010-06-24 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476667E (pt) * 2003-02-26 2014-09-18 Sugen Inc Compostos de aminoheteroarilo como inibidores da proteína quinase
US7163939B2 (en) * 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
WO2012125603A1 (en) * 2011-03-16 2012-09-20 Cephalon, Inc. Macrocyclic compounds as alk, fak and jak2 inhibitors
CA2863892C (en) * 2012-03-06 2016-08-30 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
EP2836485B1 (en) * 2012-03-17 2018-01-10 Polyphor Ag Conformationally constrained, fully synthetic macrocyclic compounds
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
BR112017007708B8 (pt) 2014-10-13 2023-10-24 Atrin Pharmaceuticals LLC Composto macrocíclico e composição farmacêutica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071837A1 (en) 2008-12-19 2010-06-24 Vertex Pharmaceuticals Incorporated Pyrazine derivatives useful as inhibitors of atr kinase

Also Published As

Publication number Publication date
MX2017004515A (es) 2017-10-31
BR112017007708B8 (pt) 2023-10-24
EP3207031A1 (en) 2017-08-23
IL251595A0 (en) 2017-06-29
US9663535B2 (en) 2017-05-30
JP6678679B2 (ja) 2020-04-08
ES2879441T3 (es) 2021-11-22
BR112017007708A2 (pt) 2017-12-19
MX389198B (es) 2025-03-20
CA2963973C (en) 2023-01-10
EP3207031A4 (en) 2018-02-14
BR112017007708A8 (cg-RX-API-DMAC10.html) 2017-12-19
BR112017007708B1 (pt) 2023-07-25
US10196405B2 (en) 2019-02-05
AU2015333738B2 (en) 2020-03-26
KR20170082532A (ko) 2017-07-14
WO2016061097A1 (en) 2016-04-21
EP3207031B1 (en) 2021-04-14
AU2015333738A1 (en) 2017-05-04
CN107108527A (zh) 2017-08-29
IL251595B (en) 2022-04-01
JP2017531041A (ja) 2017-10-19
US20170226130A1 (en) 2017-08-10
CA2963973A1 (en) 2016-04-21
US9981989B2 (en) 2018-05-29
US20160102104A1 (en) 2016-04-14
CN107108527B (zh) 2022-08-02
US20180230168A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
US10196405B2 (en) Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors
CA2969090C (en) Triazolopyrimidine compounds and uses thereof
CN107922431B (zh) Hpk1抑制剂及其使用方法
JP5389785B2 (ja) キナーゼ阻害剤として有用なチアゾールおよびピラゾール
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
WO2018031680A1 (en) Novel compounds, uses and methods for their preparation
EP3472161B1 (en) Triazolopyridine compounds and uses thereof
JP2016512816A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
JP2013526540A (ja) Ａｔｒキナーゼ阻害剤として有用な化合物
JP2016512815A (ja) Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
CA2785923A1 (en) Therapeutic compounds and related methods of use
JP2010528021A (ja) キナーゼのインヒビターとして有用なチアゾールおよびピラゾール
JP2010524962A (ja) オーロラキナーゼ阻害剤のための創薬法
CA3163389A1 (en) Biphenyl derivative inhibitor, preparation method therefor and use thereof
CN104725249A (zh) 苄胺类衍生物及其在药物上的应用
JP2016540773A (ja) Ａｔｒキナーゼの阻害剤として有用な化合物
CN108558833B (zh) 吡唑醇类化合物、其药物组合物及其在药物中的应用
KR20170067299A (ko) 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도
JP2014530202A (ja) コリンキナーゼ阻害剤として有用な化合物
HK1235837B (en) Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
HK1235837A1 (en) Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors
CN106065018A (zh) 取代的吲哚化合物及其使用方法和用途
HK40057478A (en) Hpk1 inhibitors and methods of using same
TW201629071A (zh) 稠合雜環化合物
CN109988171A (zh) 八氢吡咯并[3,4-c]吡咯衍生物及其用途

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4